Replay available

CelLBxHealth (LSE:CLBX) — Preliminary results for the year ended 31 December 2025

Preliminary results for the year ended 31 December 2025 hosted by CelLBxHealth (LSE:CLBX) on Investor Meet Company, held 2026-06-22.

Mon, June 22, 2026 at 6:00 AMendedReplay
CelLBxHealth (LSE:CLBX) — Preliminary results for the year ended 31 December 2025
Company
CelLBxHealth plc (LSE:CLBX)
Date
Mon, Jun 22, 2026, 6:00 AM ET
Replay
Watch the replay on this page · 1 h 5 min

On 6ix: 6ix.com/event/cellbxhealth-plc-clbx-preliminary-results-for-the-year-ended-31-december-2025

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good morning, and welcome to the CELLBX Health PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I'd like to submit the following poll. And I'd like to hand you over to Peter Collins, CEO. Good morning, sir. Thank you. Good morning, everybody. Peter Collins, CEO at CELLBXHEALTH. I'm joined this morning by our executive chairman, Jan Groen, and our head of finance, Sinead Armstrong. So let's get moving. So key highlights about CELLBX and the exciting opportunity in front of us and the the the reason, I guess, everyone's gathered here.

0:49 We have a key platform for better understanding of cancer biology, identifying patients who would benefit from important therapies and to enable drug companies to develop more therapies to to address a huge number of unmet clinical needs in the oncology space. So well established with a leading platform with high recovery and viability rates. We understand very well now that in a in a in a blood test, ctDNA falls short in many areas and only via circulating tumor cells can you address the full picture in a multiomic analysis of what's coming or or what's the characteristics of the tumor.

1:35 Well established on three commercial pillars of instruments consumables. A farmer and CRO services business plus laboratory developed tests, we've got a significant installed base across academia and and globally. We've put in place some anchor pharma and clinical partnerships since our reset at the end of twenty twenty five and beginning of twenty six. Recent announcements you'll have seen with the master service agreement with AstraZeneca and initiated two clinical studies with AdventHealth who acquired a platform for their work, which we're very excited about, and you'll hear more in presentation. And we've also put things in place to for our partnership with the NHS, which would enable a significant number, ten or fifteen percent of the non small cell lung cancer patient population to potentially get access to drugs that they very effective therapies that they can't currently get.

2:35 We've rightsized the cost saves the cost base of the business was over 6.6 annualized cash operating cost savings versus last year. This would have started in action in '25 and refocused our commercial approach, leadership across across the team, and accelerated path to positive EBITDA at the end of twenty eight. So company is moving forward nicely against the new strategy, which we pulled together and was the basis of the fundraise. In November, consolidated onto one site, excellent facilities over 6,000 square feet of lab space. ISO thirteen four eight five certified, SOC two for pharma, and a new focus team would reduce the headcount by approximately 60% went from circa a 100 and or gone from circa a 110 employees at the end of twenty five down down to 35.

3:35 Platform has both good validation and multiple cancer types and a significant patent portfolio. And we've addressed some key areas in terms of standard care workflows with already in the first part of this year for increased recovery rates and viability of cells for further analysis. Platform was already well validated in terms of significant publications over a 120 publications, active sites in over past ten, fifteen years has processed over 250 samples. Well well in the cost optimization areas described earlier and reduced our our cost this year to 6,700,000, and cash in the bank at the end of q one was 4,300,000.

4:25 So moving forward now with a a well characterized pipeline on the commercial delivery side with very well put together and well understanding, yeah, US leadership on the commercial side, which is primarily where we expect most of our revenues to come going forward and expected a 50 expected 50% increase on revenues from 2025. The opportunity in front of us is is significant, and we're able to get in the play a significant role in general in developing the next generation of precision cancer diagnostics with partners. The market opportunity is currently valued at 500,000,000 projected to reach 1,100,000,000 plus by 2031 with a CAGR of 10.4%.

5:19 There is an absolute need for sort of circulating tumor cells both in patient patient management and in drug development. As of now, I've, this year, been to the American Association of Cancer Research and the American Society of Clinical Oncology, which are the two biggest oncology meetings held annually for, you know, from a for a global audience. And from the podium, CTCs have been referenced, data shown, and questions responded to by, you know, the major key opinion leaders of CTCs, you know, becoming into standard of care clinical utility as we speak now. So exciting time for the company. CTCs are both complementary and new unique beyond circulating tumor DNA.

6:11 We've got a new business model, which has shifted away from science to commercialization and only pursuing opportunities which provide revenue in the near and medium term. And that's driven by a partnering approach both with lab services providers and the diagnostics and tools companies that provide the equipment and workflows to to generate data from those environments. So we're able to address multiple partners across the ecosystem of drug development and then through to the clinical tests that physicians use to manage their patients. So exciting time. We have a well qualified sales pipeline that we're able to to have been able to build on. And after a reset, then moving moving forward, we're excited about how we can build the pipeline moving forward.

7:04 It's a new management team with strong experience in the commercial and the clinical space and say very, very focused on delivering revenues and profitability as rapidly as possible. And our restructure has been focused solely around our ability to deliver on these specific revenue generating projects. So essentially, we're we're now able to be part of addressing some of the blind spots that exist in the current cancer testing paradigm. All patients get a tissue biopsy at diagnosis, but that's not a process you can ever repeat on a regular basis. And the tissue itself from the original biopsy is restricted in that cancers evolve over time, the material degrades over time, and often lesions are inaccessible.

7:59 So there's a real need to be able to address that. CTCs can add their ctDNA isn't always present in the blood. There are well understood low shedding tumors, many types. And there is also some restrictions in terms of dynamic range and sensitivity whereby false negatives cannot be generated. We also have the scenario whereby circulating tumor cells and the CTCs, what's in the CCC clusters. A lot of work initiated by one of our major collaborators, professor Nicola Aceto at the ETH in Switzerland, and many others have followed up on his work. CTC clusters are known to have high metastatic potential.

8:45 And professor and others are now working assiduously on developing so called cluster cluster busters. Similarly, there's a whole wave of cancer tests based on ctDNA, but originally developed from a signature that comes from tissue. If that tissue is not available, you can't develop the signature. So there's a significant number of patients who currently can't get access to the testing available and CTCs play a perfect accompaniment and and add additional information. So platform itself, everything revolves around a simple blood draw, 10 mil blood blood sample, and then we take the take that blood, pull it through the instrument. You can see at the top of the the image in the middle, and then we we we very gently pump the blood through a microfluidic device or a cassette as we refer to it. And there we're able to separate cells on the basis of their size, shape, and their deformability.

9:52 We can then capture those intact cells and clusters and then recover them from the cassette for a whole range of downstream analysis, which you can see in the the blue box on the right. And that's what we can do there is is is so much more than just looking at, you know, DNA, circulating tumor DNA, which is basically coming from dead and dying cells. We're we're in a very strong position to provide the materials required for this downstream work. Recently, was an independent expert consensus. Many of the the people on on this paper are very much involved in a lot of current clinical drug trials with pharma and all supported the consensus of an integration of CTCs into standard care workflows within five years.

10:47 And that CTCs provide so much more information than we can currently get with the limits of ctDNA. And many 40% in that panel identified the Parasortics as the most promising next generation technology for clinical applications. And this is because of our unique and very gentle approach to recovering cells and keeping them in the best best possible condition for downstream analysis. So it's we're definitely in the in the in the right place at the right time with real need to use CTCs. So in understanding tumors better in monitoring patients and and in drug development. CTCs are able to do what CTD they cannot when there's no tissue available.

11:36 As described, there's a when you have a low shedding cancer, we can see circulating tumor cell clusters, which you can't with ctDNA. We're then able to do a whole series of functional and drug resistance biology, which you can't do with fragments of DNA. And we're able then to look at the characteristics of individual cancer cells that we know alive and would have recently come from the tumor itself. So that that ability to look at single cell omics is very powerful. And again, we can we can then do repeat sampling on a multi dimensional basis. So basically, are able to transform inaccessible tumors into actionable biology, and thus we extend precision medicine beyond the current paradigms of tissue and ctDNA.

12:28 The market is estimated to be 1,000,000,000 opportunity by twenty twenty thirty one. We were able to see that move now from circa 400, you know, four hundred four hundred, 500,000,000 at this time and moving forward to potentially up to 1,150,000,000 in in total total addressable market in 2031 with a very good CAGR at 10.100.4%. And we're able to participate there with our our instruments and cassettes, other reagents we provide and with our farmer and laboratory services, which not only we run-in house, but also with many other partners in the in the ecosystem.

13:17 The platform is well validated. We have 61 sites with a 102 instruments working at the moment. Say, 250,000 samples that have been processed over the last ten years or so. And, you know, 120 plus peer reviewed publications across multiple tumor types. And the platform itself has has all the required regulatory and quality characteristics to work successfully with our pharma and CRO partners. And we have a a good a good patent portfolio to support that. Bottom right hand corner is a number of partners we've we have or previously worked with AstraZeneca and Ematics are our live partners as we speak, others that we previously worked with. And we have excellent work going on in a number of sites around the world with multiple pharma support or work in those in those labs.

14:17 So the application across the cancer care continuum is a very attractive space for us to operate in because there are so many options where we can provide help here in the in the pharmaceutical world. Many companies now have a pipeline that includes the antibody drug conjugates, the radioligand therapies, and other cell therapies, which all require an understanding of proteins or so called epitopes on the cell surface of the cells that you ideally wish to direct the drugs to. You can't see that with circulating tumor DNA and it's very difficult to do from the original tissue block. The the the optimal way to do this is to be able to identify, you know, cells that have come from the tumor, and that's most easily done with circulating tumor cells in the in the blood. It's an exciting sign for the company as as we move forward now with our partners across the continuum, and we can then address both the fastest growing area of of cancer testing at the moment, which is the MRD space where companies like the Terra now are running, you know, hundreds of thousands of tests on patients every every year. And it's the you know, I think they have a market cap of about 35,000,000,000 currently based on the fact that ultimately, t d a guided therapy is is is

15:48 super important across all patient groups. But the the fundamental challenge with MRD is it's not gonna tell you enough about what therapy switch the patient to. If you combine CTCs with that, then you're gonna get that information to say, okay, this is the direction of travel of the tumor, and these are therapies we should go on. Similarly, so that's very much broad based that we have specific applications in in a very large cancer group like non small cell lung cancer. And then we can also address issues for rare cancers where often tissue and ctDNA is unavailable and say another very specific area of circulating tumor cell cluster biology, which is, you know, pan tumor associated with metastasis.

16:36 There are a number of groups who are working on developing these so called cluster busters. So we've anchored a number of partnerships to derisk our revenue plans for '26 and '27. AstraZeneca is the first of what we hope will be a significant number of biopharma agreements. And that enables us not only to do testing in house, but also to be able to work with our partners in the CRO in the CRO world to have an amplification effect on the number of projects that we can be involved in. We don't have to do them all, drive them all. But the Plastaltics and the cassettes are at the are at the core of those. Similarly, the partnership we just announced with AdventHealth, who are one of the largest private health care providers in The US, circa 20,000,000,000 operation and the better part of 50 hospitals.

17:32 They've started these two clinical studies in cancer patients, which is essentially an approach to being able to monitor cancer patients remotely using a blood test, and it's been demonstrated that patients who embark on moderate exercise have a better, you know, have better relapse rates and also overall survival characteristics. Paper recently published in New England Journal of Medicine and say part of a program, which I think is well accepted, you know, in every health care system of wanting to use a blood test to be able to monitor their patients remotely and only bring them into hospital when you absolutely need to.

18:19 We've say with our active active programs with academic centers and CROs are moving forward, which again, pulls pharma in one side and then develops delivers laboratory developed tests and clinical utility on the other. And say, and we think the so we think the NHS well, Marcin project, we've moved forward enabling an additional ten or fifteen percent of lung cancer patients to get access to available and very effective therapies. Would have a knock knock on effect globally. And a bit more about that that specific program and how it doubles up, you know, it's the largest, you know, large most prevalent cancer globally, certainly here in The UK as well. CtDNA has certain limitations there, something that we order ten, fifteen percent.

19:08 The test is uninformative. So at that point, these patients can't be biopsied. So the ability to reflex where there's no information to using CTCs to identify actual alterations that would see patients eligible and getting access to those drugs is is super important and this is a well recognized, well understood, you know, phenomena. So this project we started with the NHS will will work towards increasing the number of patients. It will support the NHS's KPIs, which requires a treatment plan within twenty one days of a diagnosis. Obviously, you've got no information on a patient here. Ten or fifteen percent of them not small cell lung cancer patients is roughly six thousand patients in The UK. So there's a lot of patients who you don't really have an effective treatment pathway for, and it'll help generate the real world evidence to enable national commissioning further further down the track. Obviously, any assay will have to be validated in house in the in the in the laboratory at the Royal Mars that currently offers the Marsden three sixty test.

20:19 So we've reset the company and funded it funded to move forward on a new trajectory and growth path. We had 4,300,000 in the bank as of the end of thirty first of March. We've made a tremendous amount of cuts and cost savings as rational as possible over 6,600,000 annualized cost savings this year, and we expect our running costs operating costs in 2026 to be circa 5,500,000. The revenue guidance that we recently provided is a 50% increase on the revenues we we had last year, and we're funded through into twenty twenty twenty seven. So we're, you know, confident about the revenue trajectory that we can build on with the current key, you know, anchor accounts and partnerships we've been putting in place and work with other partners that's currently ongoing.

21:20 From a capital and funding perspective, we have a number of options open to us. Obviously, we'll be delivering operating cash from the current business. We have commercial milestones that obviously tied into deliverables, which will, you know, clearly become part of the operating cash that we pull in. And then there's also a number of strategic collaborations with with customers or industry partners that we believe are open to us that will provide non dilutive funding. Equally, with the very strong and new board that we've put in place and excellent relationship with existing shareholders, we, you know, we've got a we've got a good dialogue going forward to enable to leverage the equity capital markets as and when is what is required.

22:11 So some key catalysts moving forward to the end of twenty twenty seven. Say AstraZeneca was was pivotal for us as was as was AdventHealth. So it addresses pharma and clinical utility and enables us to work more closely with the academic and CRO community, and we can see that expanding out by the end of first half of twenty seven. The NHS lung program data, we expect to have read out by the end of the year, and then we move it to the next stage of supporting that regulate regulatory development with the with the milestone. And by the end of twenty twenty seven, given other work that we've done in terms of improving both the pre analytic side of securing the maximum number of circulating tumor cells in the best possible condition is is gonna see a, you know, an amplification effect with a number of partners that we we're currently working with establishing workflows for a number of of of key downstream analysis.

23:21 We've as part of the reset, we now have a a new management team and a board, which is absolutely built for the next stage. Our chairman, doctor Yan Groen, is formally the CEO of MDX Health, which is a company he transitioned from from from Belgium for about fifteen years ago now and took that and reestablished it on the Nasdaq in the in The US. And that's a $100,000,000 plus business going forward and has worked in multiple other organizations across the European US divide with a significant amount of success. Similarly, I've been working in a precision medicine area now for the past twenty or so years and moved, you know, with key areas of of what was initially the the CDX revolution, the companion diagnostic revolution, through into liquid biopsy and now MRD.

24:22 Leading to three strategic buyouts. Our board, very very experienced and knowledgeable board, sector experienced on execs in both the private and the public marketplaces and direct experience in biotech. So we've got experience in the AIM and Nasdaq across the board and and and clearly these with Yan and myself, a really good understanding of of operational and commercial requirements to build a successful business. Our head of r and d, Lavanya Silva Palan, we're very fortunate comes out of the Vogelstein, Johns Hopkins group.

25:08 But was but Vogelstein was at one time the most cited scientist on the planet. He he was part of founding companies like Exact Sciences, which I'm sure many of you will be aware just got acquired for a a mere 23,000,000,000 by Abbott. There are a number of I mean, Bert and his group of other most successful, you know, academic department, you know, on the globe for a significant number of businesses. And Lavanya was lucky to work both in the transactional oncology group and also in a number of the companies that was spun out from that. Very fortunate there. We have a new commercial leading, Christina Doris, spent the past fifteen years specifically in cancer diagnostics and led teams and built businesses in the with with Garden Health and most recently Epic and Menarini in the CTC space.

26:04 Similarly, heading finance is Sinead Armstrong who's been with the company many, years and has a significant experience with aim listed companies, capital allocation, and obviously all the cost discipline required to work to manage this business. And last but not least, Michelle Munson, who's our chief of staff and HR director with a a good background in pharma and biotech prior to and so we've got a very very good team on an operational day to day basis and a board of non execs who and and the board itself, obviously, with Jan and myself on the world. We have a really good understanding fundamental understanding of the of the business. Excited about what we can deliver as a team.

26:52 Now move to the financial results and hand on to Chenay. Thank you. Hello, everyone. Financial highlights for the year ended 12/31/2025. We had revenues of 1,400,000, rather challenging market conditions and slow commercial conversion than we had anticipated down from 2024 of 2,900,000. Our product and services revenues of 1,100,000 were close to the previous year. Our pharma services revenues were where we struggled because of slow commercial conversion. Gross margin gross profit margins were held at 62%.

27:40 We had an operating loss of 19,200,000. This is represented by operating costs of 21,000,000. Of this, cash costs were 14,500,000, which which includes restructuring costs of 1,200,000. Non cash costs were 6,500,000, and they were they were 3,800,000 of one off impairments in that number. The loss after tax was 19,500,000 that compares with 14,200,000 in the previous year. In December, we had a successful fundraise. We raised gross proceeds of 8,400,000, net proceeds of 7,400,000. And at the end of the year, we had 7,300,000 in cash.

28:28 After q one, we had 4,300,000 in cash, accounting for a run rate of 1,000,000 a month for the first three months as we got through the restructuring period. Since since the end of q one, the run rate is down to less than 0.5 per month, and we expect that to increase or sorry, decrease steadily for the rest of the year, coming out more of an average of 600,000 for the year. In terms of financial recess, based on the pre pre restructuring costs in terms of annual cash burn, we're looking at 14,500,000 in '24, decreased 13,100,000 in '25 and down again to 5,500,000 in 2026 and expected to decrease further in 2027.

29:27 Gross margins, we're trying to retain it at least 65% in 2026, which good margins from products and and sometimes brought down slightly by the the pharma services. EBITDA, we had 13,000,000 of EBITDA this current year, and that will we're hoping, be reduced down to 3,900,000 loss in in 2026 and hopefully positive from 2028. Headcount, which is a driver of of more than 50% of our cost historically, we had a 130 headcount averaged in 2024.

30:14 In 2025, that was reduced to a 108. And currently, we're looking at an average headcount for 2026 of 35, which may be reduced down to as low as 32 by the end of twenty twenty six. So the overall operational restructuring has been completed. We resulted in in quite significant cost savings, as you can see. 60% more than 60% reduction in headcount were consolidated into one single operating location in Guildford now with having having surrendered one lease at fairly good rate. And we we have spent quite a significant time renegotiating supplier and service contracts and reducing costs of right throughout the business, and we're continuing to do so as as we move through the year.

31:13 The focus is very heavily on revenue generating activities and projects, and any additions to headcount will be directly as a result of revenue generating activities. Thanks, Shane. So from an offer operational perspective, some some significant highlights here, and I would really like to emphasize what a fantastic job the new team has done ably supported by the board. We had to move from two sites to one site. We had a laboratory on both sites. Huge amount of work to transition. And then also get that previous building back into good shape to hand hand back to the to to the landlords. But team did a fantastic job and in the process made during the last six months has made some significant improvements in our ability to both recover and provide viable cells for downstream analysis. And so the research team or the r and d team went from better part of 60 people to to circa 12.

32:21 And so, yeah, team's done a fantastic job there. We've reassessed the pipeline, ensured again that both all the projects that we operate on are driven purely by, you know, commercial reasons, return on investment in the short, medium term, and pulling all the right partners in place. So I think the the team should be really congratulated on on what we've got to there. The corporate rebrand to CELLBXHEALTH was to CELLBXHEALTH was completed to ensure that we could, you know, be revised and aligned with that strategic direction. And obviously, there's opportunity for me to come in as CEO, strengthen the board with three non executive directors. And, obviously, we're we're we're well set now with some good original some good sorry. Good original. Some good strategic strategic collaborations with QIAGEN, MRI, and Illumina, Roche Diagnostics. So that's a broadly covers, you know, some major diagnostic companies, labs, and also tools providers that, you know, you know, provide equipment and and systems that are prevalent across the entire lab environment. So we're we're really well embedded with the right partners across the ecosystem that supports both patient management and drug drug development and and cancer research.

33:46 And so during that period, you know, AstraZeneca has been signed and we begin moving forward with work there. AdventHealth was important. Winfred was those studies, and I just described the the health services is is a is a is a super opportunity because it will be globe but, you know, if it works out as we anticipate, there will be global global implications for that. And maybe it's a good good example as that as I recall it is that in the breast cancer space is a recent paper that came out from one of the leading groups as a combination of the University of Athens, but also Weill Cornell and professor Massimo Cristoinelli, who's a very well known figure in in in the cancer world. And a paper there showed where they were comparing mutations in a gene called ESR one, which is very closely associated with patients who have so called HR hormone receptor positive breast cancer. These were advanced patients, and they were looking at methylation of that gene and mutations in the ESR one gene in ctDNA and also in the circulating tumor cells.

34:58 And the ESR one mutations are significant for getting patients on next generation drug drug currently approved is drug called elacestrant from Menarini, but there are a number of other in development including AstraZeneca's camis camisestrant. But, anyway, the the CTCs showed a prevalence of ESL one mutations over sixty sixty five percent of the time versus in the ctDNA, they were only picking up these mutations. Just over twenty five percent of the time. So real food for thought there and I think one of the reasons why professor Francois Clement Beader at ASCO when asked the questions, what is the role of CTCs? Is there any role? Are we gonna be using them?

35:48 It was a it was a resounding yes. And, frankly, if if I had or knew of someone with advanced breast cancer and they'd had a negative result on c t d n a, I think I'd be asking for my circulated tumor cells to be looked at if at all possible. So outlook for the next eighteen months, obviously, based around our product sales, you know, and lab services and then the the test that we both develop in house and with partners, you know, we will remain, you know, you know, really, you know, good and prudent stewards of stewards of cash and look for all the efficiencies we can. We've already done a fantastic job in reducing the cash burn in the short term and expect to reduce that further to 5,500,000 to 26.

36:35 In the process of efficiencies, we'll see increased margin and 50% increase on revenues in '26 versus '25, and we remain on target for EBITDA breakeven in late twenty eight. So all in all, hope you agree as a very exciting, you know, investment thesis and a place to be for the company. It's very focused. We have a a leading platform, a credible path towards scale. We're well differentiated from not only from addressing the CTC platform, but obviously, as as complementary and unique to doing things that CTD and our tissue cannot. We're already validated at a at a good scale in terms of publication samples, etcetera. So the credibility to work with the platform already exists. And we've already done more work to ensure that the performance we get is is at an improved level to ensure both in house and with our partners, we get the best possible experience.

37:36 The anchor wins are in place. There are more to follow and some other announcements that we will put together over the next next couple of quarters. You know, well funded through, you know, and, again, a big thanks to everyone who contributed to in investment and and enabling us to be able to restructure back in November. Cost savings have been actioned. We've said what we what you know, we've done what we said we're gonna do. You know, the new commercial leadership, I think, is is is is really coming into play now, and we are funded through first half of twenty twenty seven. So thank you very much for for your time, and happy to address any questions. That's great. Thank you for updating investors today.

38:22 Could I please remind investors to submit your questions just by using the Q and A tab situated on the right hand corner of your screen? And for your reference, a recording of today's presentation will be available on the Investor Meet company platform shortly after the meeting has ended. Guys, as you can see, we received a number of questions during today's presentation. If I could just hand over to Paul McManus of Warbrook to host the Q and A and to read out the questions to the team and then give responses where appropriate to do so, and I'll pick up from you at the end. Thank you very much. We've got quite a few questions, some presubmitted and then some that have come through. So we'll try to get through those before the before the hour is up. One question that was presubmitted, it also has cropped up in in in the presentation, is about the Solaris collaboration asking for really an update on the the opportunity or the the status.

39:10 And and just the question that we had pre submitted, you know, would you resume this collaboration? So can you just explain what status the collaboration is? Yeah. The the the the the current status of the collaboration is that it is in status at this point in time. We don't have the bandwidth to to drive that program forward. That was originally part of the previous strategy, which was around building all these tests ourselves. And so at this stage, we don't have the the bandwidth to be able to do that. So for the time being, you know, we know the strategy we've embarked on. We we intend to continue down down that route. I think there were. There was one other question that kind of looked at, again, studies from the past. And I say we when we're when we're in a position with partners to address those, we can come back to them. But for the for the time being, we can't. We don't have the resources to be distracted away from the critical things we see now in terms of driving the business forward in a partnership approach.

40:17 Talking of driving the business forward, somebody asks, how many big pharma are you in talks with now? Currently, we have good conversations going with about half top 10 pharma. So let's say it's having having worked both sides of the fence here many times before. You need to be careful about how many big pharma you wanna work with. You'd love to work with all of them, but they're, you know, we barely count as something on a pinhead compared to too many of them. So with with the the people we wanna work with, I think, and who want to work with us ahead of the curve, I think we're we're very comfortable about the the partnerships we we currently have, and I'm sure it will see, you know, a a multiplication effect once they see data coming out and more more projects in place. Along those lines, are you still co marketing ParSortix with Illumina? And can you give us an update on that? Yeah. I'm not sure we were ever co marketing with Illumina. Obviously, I'm gonna plead the fifth and say this absolutely predates predates my time. We do have good collaborations running with Illumina because they understand the importance of being able to look at circulating tumor cells and do single cell genomics, and they need a workflow.

41:38 I mean, everything everything in terms of doing any downstream analysis is only as good as the pre analytics. Yeah? It's, you know, it's I nearly used a bad word. It's rubbish in rubbish out. We we work very closely to ensure that we have the right downs the right downstream or right upstream protocols to get the cells in the right place. And then there are multiple applications, either DNA or RNA that we're working with them on. Once we have more to share, we will we'll do so, but we're definitely working with a great partner there. Thank you. A a question on competitive positioning. The independent expert consensus published in 2025 concluded that 90% of experts expect CTC analysis to become part of routine clinical practice within five years, yet only 40% identified PLC's as the most promising next generation platform. From Michelle's perspective, what does management believe is still required for CELLBX to strengthen its competitive position and emerge as a leading commercial beneficiary of CTC adoption?

42:42 And what specific milestones, partnerships, clinical evidence, or other commercial achievements should investors watch out for which would demonstrate that your product is gaining a durable competitive advantage rather than simply participating in the growth sector? Okay. Great. Great question. How long have we got? I mean, it's it goes back I mean, the the thing is you you describe about developing an entire market there, which, you know, let's be realistic. You know, we have money through to the, you know, twelve twelve months twelve months from from now, and we're doing this in a step by step basis. And fundamentally, any of these relationships to build the market are always data driven and with and with the right partners. So we say we we can only work with a certain number of partners and and move through on step by step by step basis.

43:34 Generating high quality data with partners is the, you know, is the only way we're going to do this. And I think we've already got a good number of partners that we're working with, whether it be, you know, AstraZeneca or AdventHealth. There are other CROs involved and the providers of both equipment and kits that drive that business. But we get we will have individual programs that we're working on where we make sure we deliver high quality data. And that's the way we'll be able to to move this forward. You know, clinical evidence and utility is a very demanding bar to to achieve. There are relatively few tests that have ever demonstrated true clinical utility. Most of those are in oncology, and the generation of the clinical utility data has basically all been supported on the back of those clinical trials.

44:30 And so that is our intent, but it will take, you know, more than a couple of years to be involved in a phase three clinical trial that has all the clinical data says. This is this is prime time. In the meantime, relationships like the Mars then successfully showing that you can reflex, you know, as, you know, a small but important number of patients to a test that enables to identify alterations to get on drug is the way we'll move this forward. So, you know, stepwise, one at a time, work with work and work with the right partners. So I think we're yeah. Confident and happy that if people want the best quality cells and the and the best possible recovery cells to work with, then the ParseAutics does does what it says does what it says on the tip. In terms of big pharma, how they think about CTCs, there's a question from a shareholder about whether, you know, has thinking changed over the two or three years, you know, compared to two or three years ago?

45:32 Has the thinking of about CTCs changed in terms of industry engagement? Yeah. No. No. Absolutely. I I spent five years heading diagnostics at GSK and biomarkers and diagnostics for their immunotherapy group, having previously done a lot of work in the companion diagnostic space. The there's a real understanding that ctDNA is basically, you know, kind of, you know, hit the buffers in terms of more innovation and and the information we can get from it. CtDNA is of little or no value in in settings where you need to know something about the expression of all the proteins, epitopes that exist on the cell surface in order to effectively deliver the drugs. We're talking antibody drug conjugates, what the antibody is gonna bind to the epitope, the radioligand therapies. Again, this is an antibody with a radioactive payload. Again, looking for the right epitopes.

46:33 Similarly, any cell based therapy is looking for, you know, receptor epitopes to go to. You can't get that with c g d n a. You can't you can't get it from tissue. You know, that's been demonstrated well now. So circulating tumor cells, live cells, you know, from a simple blood sample is the best way to be able to do that. So there's a huge amount of interest and drive. And if I think back, for example, to to AstraZeneca, delighted to be working with them again. You know, I've worked with them now over over twenty years, three drug approvals that I've been very fortunate be part of, you know, resettles, imertinib, divalumab. They've had a circular well, they've had a liquid biopsy group running for many years now. But up until recently, it's primarily been a ctDNA working group. Well, now it's addressing circulating tumor cells and other components like extracellular vesicles in the blood, and it's it's really being taken, you know, very seriously. As you know, they are the with nHERT who they are the the leading group in the ADC space along with their partner, you know, DSI.

47:41 So, yeah, very excited about that. And there's no question pharma does tend to move a little bit in a herd mentality. So you can you can see once other programs are known about moving forward, then, you know, we'll we'll we'll see that momentum moving forward. Definitely, pharma takes it much more seriously. Following on to that, for the momentum to move forward, Is there key evidence that Steve still needs to be generated before it becomes a meaningful commercial opportunity? Yeah. No. Of course. I mean, at the end of the day, we've got to run the studies and demonstrate that the circulating tumor cells deliver this, know, unique information that you can you you can effectively only get from CTCs on a consistent basis. And I think that's where so much of that is about the preanalytics prior to to make sure you give yourself the best possible chances of of of having access to the circulating tumor cells.

48:39 Clearly, there are a lot more circulation tumor cells in the in the blood of a patient with advanced disease than there are with someone who's at stage one. So, you know, as ever, this is always nuance, you know, stage one through stage four, and then the disease will have an impact. But, you know, picking on the on the on the right on the right tumor types at the right time, again, is is the smart way to do this. And that's that's one of our criteria is what, you know, we're we're we're being very specific about who we work with. We're not available to work with anybody on any project knowing that it may be low hanging fruit in terms of some revenue, but there's a high likelihood that the data may not be good enough. So we're I think we're we're smart enough and experienced enough group to make some good decisions about the projects we want to be involved in as well.

49:29 Shareholders asked about recent recruitment of scientists. Are you have you made hires to support active customer programs or is this ahead of anticipated future demand? I'm not sure. Yeah. Given that there's only 12 of them, then I'm absolutely certain it's all about supporting active programs. And at the point we see those opportunities growing significantly, clearly, we'll we'll be back we'll be back to raising the appropriate funds required to to deliver more at a at a at a greater scale, but very much the here and now. Then a question about the blood samples. In the past, the company has mentioned about having the 7,000 blood samples. Are you able to comment about long term commercial value of this data set as well?

50:19 I mean, I think I think the I think there is hopefully, you know, potential in that those biobank samples. Currently, those studies were all based around developing our own tests, which as I as I recall again, Chenay, correct if I'm wrong, we did have a CLIALab facility in The US where we were intended to drive these types of tests, which are really I mean, you're only gonna get paid for the cancer types these look at if you've got a Moldex coverage decision for an LDT in The US. Essentially, you know, we we not in a position to do that now. We still have that lab facility in The US. We've actually sub sublet part of it to a very good CRO and development partner who we're working with. But in the short in the short medium term, we're we're we're not resourced to go and take that kind of a program all the way through the Moltex process because you'd have to do all those, run all samples, get the data.

51:21 You've then got to submit it, get it published Only upon a publication can you go to, you know, to the mold the mold mold ex group, you know, to to to Palmetto Palmetto to get an approval. Yeah. It's a it's it's it's a very expensive process. And then once you've got through that, that's probably gonna take you at least a couple of years, maybe three years. You've then got a a commercial sales force to market it. Well, yeah, that's a that's a that's a that's too big a lift for us at this stage. So we'll we'll address it with a partner at the right time. We've got several questions on cash, so if we could wrap them all up together. But, obviously, you talked on slide 16 and your capital and fundraising options that you have available and that you made off on slide 20, you explained about the current cash burn and the reduction there. But can you just clarify or sum up again to answer those questions that have come through? What is the cash position? What are the steps that you're taking to get to being self supporting?

52:24 You know, I think you've talked about it already, a push for sales, increasing revenues as well as as cuts. And then what options are available to you if there is a need for cash? Yes. Absolutely. As I said, they I think there's some questions around the spend in the first quarter and how then we can see the the the funds going through to q q two twenty twenty seven. The cash position, well, we did spend 3,000,000 in in the first quarter. We completely restructured the company at that point. We had more than 1,200,000 of that 3,000,000 was in restructuring costs. The cost base is now completely under control. We are and we're still managing to make savings as we as we right size ourselves.

53:13 The the headcount is is dropping. We had committed to less than 44, and we're now down at an average of 35. So cash is always a concern for us, and and it will always be relies heavily on the revenue coming in. We were on had a slow start to the year in terms of revenue and income coming in because, say, q q four twenty twenty five was much poorer. It's usually our our strong month. Our December November, December, August, very strong for us because we were going through the transition at the end of the year. A lot of our customers got a little bit nervous. We saw that through q one. So the income in q one was poor, but we're now seeing that ramp up really fast.

54:00 So the the impact in that 3 millions in the first three months was was on top of the restructuring. Was it was it was enhanced essentially or made worse by the fact that the revenues weren't coming in. So that now seems to be much more under control as well. We are starting to see a lot more traction, and and it it the customers are now sort of settled down a little bit. We we do have some other income streams as well. I think people are worried about in terms of the RD tax credits, will be about no point 8,000,000, which we should receive at the beginning of well, sometime in q in q three. We I think in terms of funding, yes, we are clear that they fund at the moment to take us out to q three or sorry, q two twenty twenty seven, at which point we we will need another source of funding.

54:57 Whether that be, as Peter said, by equity funding or working with existing shareholders or or collaborations. That, I think, is a question for Peter. Yeah. I don't know. Obviously, that that any of that engagement is all best based on continuing value inflection points with partners based on the data that we're generating in selective studies that we're running at the moment. And, you know, seeing that revenue curve rise along with the the potential as you mentioned. There's there's always an element of, you know, how do you anticipate the the hockey the hockey stick here. And this I think in terms of the growth we're gonna see in CTCs, you know, it it it may may well be given the the absolute need to have CTCs available for so much work. I think at some point, there will there will be a significant, you know, inflection in terms of the demand for use and and and and work that we can do. And then we need to be prepared as a company with the board and with our investors to be able to capitalize upon that.

56:08 Similar question related to that. Are there particular technical, clinical, commercial hurdles that you think you have to get over to to to see that revenue rising? Is there are there certain things that you think you need need to deliver? What what what's the challenge? I think the the the the challenge, frankly, is always the it's the veracity of the science that you do, and it's, you know, dealing with the fact that you are, you know, to be dealing with a large amount of biological variables. So you have to make sure you've accounted for those as as well as as well as possible going forward, which again means, you know, pick your battles and make sure that you do the science, you know, as diligently with as much veracity as possible.

56:58 And, you know, all the data is there that says once you've once you've got access to the cells, you know, the data rate, you can do it with it. You just you just need to do it well, and that means focus, discipline, much like we're managing the cash position. So only on the basis of the data, you have to, you know, earn the right to go forward and expand what you do. And you have to do that off a off a off a solid base with one eye on the future. At some point, if you look recently, you know, at the couple of acquisitions that are recently made by both Abbott and Roche. Abbott moving into giving themselves much more resources in the in the oncology space. So if you look at what, you know, Roche have just done with the acquisition of both Saga and and PathAI, they're trying to build, you know, a full ecosystem of tools and markets they can address. They own Ventana on the tissue side.

58:00 Saga, which I was the CEO for for for four years, took it to where it had Moldex coverage decision. You know? They can leverage both their sequencing platform and their knowledge of digital PCR. Well, guess what? You can use that all on circulating tumor cells as well as anything else. They just need enough evidence to be persuaded that this is part of the continuum that they need support in a lab. I mean, they're already preparing for the future. For example, with mass spec, they're the only company, I believe, with a program that would see mass spec, which no one ever thought would get into a clinical lab. Well, that program is in place. And ultimately proteomics, not genomics, is I think gonna tell us what to do here. And and so that those moves are already afoot.

58:45 And I have no doubt that circulating tumor cells and looking at the proteomic side with, you know, known numbers, very small numbers of cells. It's just a matter of when or if those those problems get correct. And our our job is to, in a very disciplined fashion, stay in stay in that game performing well, growing in a in a in a in a well understood fashion until we and other partners can take advantage of what will inevitably be a significant acceleration. We're getting close to the end of the hour, but I'll I'll quickly put in two two questions that we've got lot left. There are some other questions on the platform here that we just haven't been able to get to and probably require detailed answers, but that's fine. We can can give written responses for those. But just quickly, the last two. One was, you obviously, you've explained about the revenues being 1,400,000 due to slower commercial conversion that had an impact on what you were hoping to do last year. But looking forward, how do you feel comfortable about the forecasts? You've obviously said about your 50% up uplift.

59:50 And and how comfortable do you feel looking forward? What gives you the Yeah. Yeah. No. I think I think the the current revenue trajectory is is is is very achievable. And we are we we're already seeing data that we've, say, generating with partners. I'm thinking of a company we've been been working with called Bioscribe who are working in this space. They have their own lab and they have a chip based solution. They are the leaders in whole genome amplification on a single cell basis. Similarly, a transcriptome and they can they can do a methylome too. If required, you know, we've done some terrific work with them and we're working more closely with them, you know, distributable kit model, combination of kits with a platform, you know, linked to an Illumina or an Ultima sequencer or a QIAGEN digital PCR instrument.

1:00:54 You know, all all those options become open for us as we move forward. And the data we've generated to date, you know, suggests it's gonna be a really valuable tool. Again, in this antibody drug conjugate world, radioligand therapies, and cellular therapies, which are really what are now at the front end of driving pretty much every oncology pipeline. Yeah? I mean, that's really where where we expect to see all we have much of the growth as we move forward. And then the last question, I'm sure you get it asked all the time. An investor has used a specific big pharma's name to ask whether they would buy you, but we won't mention specifics. But, ultimately, is that what success is for this business in the long term that the a likely option is is a is a is a buy out, or is that Well Is that a long It's not what you're looking at at the moment. It's success in the short term. We we are focusing on building the business where we are with the circumstances.

1:01:50 But and by by definition, pharma companies and such, they don't buy that. They don't buy that. They never pay that. Yeah. They did a few in the past, but it's a disaster. Yeah. Yeah. But I think from from, you know, the focus at the moment, as you say, is is getting the business increasing revenue Yeah. And utilizing the commercial aspect of the of the technology. Yeah. As I say, we've done you know, the team has done an incredible job with the reset. Obviously, you know, the you know, don't underestimate the PTSD that goes with reducing a company from a 110 and all the relationships, the colleagues, one building to two. In a six months window, we have made tremendous strides, reset the pipeline, got the right partners in place. So, you know, we're confident that we've, you know, got the business under control, reset, and with the right partners moving forward. So we'll move forward to execute against the plan. And, yeah, excited about the future.

1:02:49 Yeah. Thanks, Peter. Thank you. Thank you for answering those questions from investors today. Before we ask investors to share their feedback, which I know is particularly important to the company, Peter, could I please just ask you for some closing comments? Yeah. No. Thank you. Yes. So yeah. So pleasure to meet with everyone. So now say I can't emphasize, you know, thank you, you know, for the opportunity to take the company forward. I mean, at the end of last year, you know, there was a question whether the company would continue to to exist and without your support, you know, it would be nonviable as I say. I think I'm, you know, very, very comfortable that we have an excellent team now, an excellent management team, a great board to work with. We've already, you know, demonstrated that we can execute on important plans to a to a good timeline.

1:03:39 Partners are all lined up in place. I think we have a good understanding of the, you know, in many cases, it's understanding the limitations of your own products and technology and, say, picking the right battles to win here because there are so many possible options. I think we're we're well set going forward. I'd say I think it's, yeah, it's been, you know, tremendous working with yeah. I'm very happy for his support here today because, know, it's it's an unusual, I think, for a company of this size in any any market to to have so much salt and pepper around the table to address key questions around how you run, operationalize these business and also turn them into successful commercial organization. So I think thank you again, and looking forward to the exciting future.

1:04:25 Thank you once again. Could I please ask investors not to close this session as you'll now be automatically redirected to provide your feedback, which will help the company better understand your views and expectations. On behalf of the management team of CELLBX Health PLC, we would like to thank you for attending today's presentation, and good afternoon to you all.

Follow CelLBxHealth plc into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Jan Groen

Executive Chair at CELLBXHEALTH PLC

Peter Collins

CEO at CELLBXHEALTH PLC

Sinead Armstrong

Finance Director at CELLBXHEALTH PLC

Alice Woodings

IR at CELLBXHEALTH PLC

More from CelLBxHealth plc